Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have earned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.00.

A number of equities analysts recently issued reports on the stock. StockNews.com raised shares of Precigen to a “sell” rating in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Precigen in a research report on Wednesday, May 15th. Stifel Nicolaus lifted their price objective on shares of Precigen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 3rd. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Precigen in a research report on Monday, June 3rd. Finally, JMP Securities reissued a “market outperform” rating and issued a $14.00 price objective on shares of Precigen in a research note on Tuesday, June 4th.

Precigen Stock Down 3.5 %

Shares of NASDAQ PGEN opened at $1.38 on Monday. The firm’s 50-day moving average price is $1.57 and its 200-day moving average price is $1.47. Precigen has a 52-week low of $0.84 and a 52-week high of $1.93. The company has a market cap of $348.34 million, a PE ratio of -3.54 and a beta of 1.73.

Precigen (NASDAQ:PGEN) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Precigen had a negative return on equity of 65.36% and a negative net margin of 1,781.72%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.54 million. During the same period last year, the firm posted ($0.10) EPS. As a group, equities research analysts anticipate that Precigen will post -0.38 EPS for the current fiscal year.

Institutional Trading of Precigen

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC increased its position in Precigen by 12.5% during the 4th quarter. SG Americas Securities LLC now owns 76,352 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 8,478 shares during the period. Fortis Group Advisors LLC bought a new position in Precigen in the first quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. lifted its holdings in Precigen by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 47,829 shares of the biotechnology company’s stock worth $69,000 after buying an additional 19,041 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Precigen by 4.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 421,788 shares of the biotechnology company’s stock valued at $666,000 after acquiring an additional 19,301 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Precigen by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after acquiring an additional 19,875 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.